Anixa Biosciences
ANIX
15 hedge funds and large institutions have $337K invested in Anixa Biosciences in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
12% less funds holding
Funds holding: 17 → 15 (-2)
26% less capital invested
Capital invested by funds: $457K → $337K (-$120K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.06K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$884 |
| 3 |
Morgan Stanley
New York
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.46K |
| 2 |
Millennium Management
New York
|
-$7.54K |
| 3 |
ClearBridge Investments
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BA
1
Bard Associates
Chicago,
Illinois
| $183K | – | – | – |
|
|
DIA
2
Denver Investment Advisors
Denver,
Colorado
| $56K | – | – | – |
|
|
3
Millennium Management
New York
| $35K | -$7.54K | -2,628 | -19% |
|
|
4
Morgan Stanley
New York
| $30K | +$6 | +2 | +0% |
|
|
5
UBS Group
Zurich,
Switzerland
| $16K | -$9.46K | -3,298 | -39% |
|
6
First Manhattan
New York
| $7K | – | – | – |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $4K | +$884 | +308 | +30% |
|
8
Wells Fargo
San Francisco,
California
| $2K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | +$2.06K | +718 | +725% |
|
10
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
EWM
11
Evercore Wealth Management
New York
| $1K | – | – | – |
|
12
Geode Capital Management
Boston,
Massachusetts
| $101 | – | – | – |
|
|
13
ClearBridge Investments
New York
| – | -$3K | -1,000 | Closed |
|
ANIX Hedge Fund Activity: Q1 2016 in Review
15 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2016, worth a combined $337K — down 26% from $457K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ANIX and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.06K. The largest seller was UBS Group, cutting an estimated $9.46K.
- 15 institutional investors held Anixa Biosciences (ANIX) as of Q1 2016, down from 17 in Q4 2015.
- Funds reported $337K of Anixa Biosciences stock for Q1 2016, down 26% quarter-over-quarter.
- 0 funds opened new Anixa Biosciences positions in Q1 2016 and 2 closed out, a net change of -2 holders.
- The largest Anixa Biosciences buyer in Q1 2016 was Tower Research Capital (TRC), an estimated $2.06K added.
- The largest Anixa Biosciences seller in Q1 2016 was UBS Group, an estimated $9.46K sold.
Based on aggregated 13F filings for Q1 2016.